TBC1D30

Across TCGA pan-cancer cohorts, TBC1D30 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TBC1D30 data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher TBC1D30 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TBC1D30 expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

SCLC, SARC, and UCEC are the cancer types where TBC1D30 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	II,III,IV	1.000	0.292	.016	7	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TBC1D30–SCLC (DFS)

Open the SCLC breakdown →